Estimating the cost-effectiveness of pneumococcal conjugate vaccination in Brazil

Vespa, Glaucia; Constenla, Dagna O; Pepe, Camila; Safadi, Marco Aurélio; Berezin, Eitan; Moraes, José Cássio de; Campos, Carlos Alberto Herrerias de; Araujo, Denizar Vianna; Andrade, Ana Lucia S. S. de.
Rev. panam. salud pública ; 26(6): 518-528, dic. 2009. ilus, tab, graf
Artigo em Inglês | LILACS | ID: lil-536492

Documentos relacionados

  1. Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults.
  2. Characteristics of endovascular pneumococcal infections; a decade of nationwide surveillance study.
  3. Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials.
  4. Health Care Provider Knowledge and Attitudes Regarding Adult Pneumococcal Conjugate Vaccine Recommendations - United States, September 28-October 10, 2022.
  5. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands.
  6. Strengths and weaknesses of pneumococcal conjugate vaccines.
  7. Epidemiologic Benefits of Pneumococcal Vaccine Introduction into Preventive Vaccination Programs.
  8. Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination.
  9. Pneumococcal Surface Protein A: A Promising Candidate for the Next Generation of Pneumococcal Vaccines.
  10. The Need for Adult Pneumococcal Vaccination in Nigeria.